Use and Outcome of Empiric Echinocandins in Critically Ill Patients

Link to article at PubMed

Acta Anaesthesiol Scand. 2021 Jan 22. doi: 10.1111/aas.13783. Online ahead of print.


BACKGROUND: Echinocandins are recommended as a first-line empiric treatment for fungal infections of patients in an intensive care unit (ICU) with critical illness. The primary aim of the study was to compare outcomes among ICU patients treated with empiric anidulafungin (ANI), caspofungin (CASPO), or micafungin (MICA).

METHODS: A retrospective cohort study in a mixed adult ICU. Patient demographics, reason for ICU admission, ICU risk scores and organ support therapies were analyzed. Outcome parameters included ICU and hospital stay, 30-day mortality and 1-year mortality.

RESULTS: Empiric echinocandin therapy was given to 367 patients (ANI; 73 patients, CASPO; 84 patients, and MICA; 210 patients) with a median duration of three days in an ICU. Patient median age was 60.7 years. As a first-line therapy, 52% of patients received fluconazole. Positive Candida cultures were found in the following samples: blood, 16 (4.4%); central line, 27 (7.4%); deep site, 92 (25.1%). Median ICU stay (ANI 6.4 days, CASPO 5.3 days, MICA 8.1 days), hospital stay (ANI 33 days, CASPO 30 days, MICA 30 days), 30-day mortality (ANI 27%, CASPO 32%, MICA 32%), and 1-year mortality (ANI 33%, CASPO 44%, MICA 45%) did not differ between the groups . The cost of antifungal therapy during the ICU period was similar in the three echinocandin groups (ANI; €1 872, CASPO; €1 799 and MICA; €1783).

CONCLUSION: Our results show that ICU, hospital stay and mortality (hospital, 30-day and 1-year) did not differ among patients with empiric anidulafungin, caspofungin or micafungin treatment in a mixed adult ICU.

PMID:33481252 | DOI:10.1111/aas.13783

Leave a Reply

Your email address will not be published. Required fields are marked *